iCo Therapeutics Announces Second Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:
iCo Therapeutics Announces First Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:
iCo Therapeutics Inc. Announces Q1 Interim Filing Update
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:
iCo Therapeutics Announces 2019 Year End Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)
iCo Therapeutics Inc. Announces Annual Filing Update
April 27, 2020, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: ICO)
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: